Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

New Approach Restores Effectiveness of Older Antibiotics

By BiotechDaily International staff writers
Posted on 29 Apr 2014
Image: Cultured bacteria showing increased sensitivity to antibiotics with the additional of a metallopolymer (Photo courtesy of University of South Carolina).
Image: Cultured bacteria showing increased sensitivity to antibiotics with the additional of a metallopolymer (Photo courtesy of University of South Carolina).
Methicillin-resistant Staphylococcus aureus (MRSA), a complex of multidrug-resistant Gram-positive bacterial strains, has proven especially problematic in both hospital and community settings.

These bacteria have become drug resistant by deactivating conventional β-lactam antibiotics, including penicillins, cephalosporins, and carbapenems.

Microbiologists at the University of South Carolina (Columbia, SC, USA) introduced a class of charged metallopolymers that exhibit synergistic effects against MRSA by efficiently inhibiting activity of β-lactamase and effectively lysing bacterial cells.

The β-lactam structure in a molecule is something that many bacteria are adverse to. It greatly hinders their ability to reproduce by cell division, and so chemists have for years spent time making molecules that all contain the β-lactam structural motif. One of the most effective bacterial defenses is an enzyme called β-lactamase, which chews up the β-lactam structure. Some bacteria, such as MRSA, have developed the ability to biosynthesize and release β-lactamase when needed. It is a devastating defense because it is so general, targeting the common structural motif in all of the many β-lactam antibiotics.

The interdisciplinary team also showed that the antimicrobial effectiveness of the four β-lactams studied in detail was enhanced by the polymer. They prepared a cobaltocenium metallopolymer that greatly slowed the destructiveness of β-lactamase on a model β-lactam molecule (nitrocefin). The enhancement was modest against two strains, but very pronounced with the hospital-associated strain of MRSA (HA-MRSA). The four antibiotics penicillin-G, amoxicillin, ampicillin, and cefazolin, were protected from β-lactamase hydrolysis via the formation of unique ion-pairs between their carboxylate anions and cationic cobaltocenium moieties.

The study was published on March 17, 2014, in the Journal of the American Chemical Society.

Related Links:

University of South Carolina



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Diagram illustrates the innovative process that could lead to more effective drugs against influenza infection (Photo courtesy of the Hebrew University of Jerusalem).

Researchers Show How the Influenza Virus Blocks Natural Killer Cell Recognition

A team of molecular virologists has described how the influenza virus evolved a defense mechanism to protect it from attack by the immune system's natural killer (NK) cells. The recognition of pathogen-infected... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Lab Technologies

view channel

Genome-Wide Mutation-Searching Computational Software Designed for Genomic Medicine

Analysis software cross-references a patient’s symptoms with his genome sequence to help physicians in the diagnosis of disease. This software was created by a team of scientists from A*STAR’s Genome Institute of Singapore (GIS), led by Dr. Pauline Ng. The research findings were published August 3, 2014, in the journal... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.